Abstract
Species of the Celastraceae family have been the target of in vitro studies for accumulating secondary metabolites with potential use as bioactive in phytomedicines. Recently, in vitro and in vivo studies have shown that quinonamethides triterpenes (QTs) celastrol, maitenine, 22²-hydroxymitenamine and pristimerine are promising substances to be used in anticancer therapy because they are …